Half-Dose Intracoronary Abciximab Bolus Improves the Mortality Outcome Compared to Standard Intravenous Regimen

Azienda Sanitaria Ospedaliera

Status and phase: Terminated; Phase 4

Conditions: Myocardial Infarction; Coronary Disease

Treatments: Drug: abciximab

Study type: Interventional

Funder types: Other

Identifiers

NCT00320229

ABCX-LD

Details and patient eligibility

About

The aim of our study was to demonstrate that, during a percutaneous coronary intervention, even smaller amounts of abciximab than standard dose, injected locally, could achieve a rapid thrombus resolution and clinical improvement without concomitant differences in hemorrhagic complications

Full description

Patients both with acute myocardial infarction and unstable angina are prone to extensive intracoronary thrombosis, leading to acute deterioration during percutaneous coronary intervention or thrombosis of the device despite therapy. Intracoronary use of abciximab has reported favourable results. We randomly assigned 84 patients to intracoronary half abciximab bolus (group A) and to standard regimen (group B).

Sex: All

Ages: 50+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• presenting with unstable angina
• presenting with acute myocardial infarction
• eligibility for percutaneous coronary intervention

Exclusion criteria

• presenting with cardiogenic shock